183 related articles for article (PubMed ID: 19442295)
1. Immunohistochemical characterization of subtypes of male breast carcinoma.
Ge Y; Sneige N; Eltorky MA; Wang Z; Lin E; Gong Y; Guo M
Breast Cancer Res; 2009; 11(3):R28. PubMed ID: 19442295
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtyping of male breast cancer by immunohistochemistry.
Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia.
Lin CH; Liau JY; Lu YS; Huang CS; Lee WC; Kuo KT; Shen YC; Kuo SH; Lan C; Liu JM; Kuo WH; Chang KJ; Cheng AL
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1807-14. PubMed ID: 19505913
[TBL] [Abstract][Full Text] [Related]
5. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
6. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
8. Laminin 332 expression in breast carcinoma.
Kwon SY; Chae SW; Wilczynski SP; Arain A; Carpenter ; Philip M
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):159-64. PubMed ID: 22427740
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic features and prognostic significance of basal-like breast cancer].
Liu H; Fan QH; Li X; Liu GZ
Zhonghua Bing Li Xue Za Zhi; 2009 May; 38(5):316-22. PubMed ID: 19575874
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Collins LC; Cole KS; Marotti JD; Hu R; Schnitt SJ; Tamimi RM
Mod Pathol; 2011 Jul; 24(7):924-31. PubMed ID: 21552212
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological and molecular subtypes of male breast carcinoma according to immunohistochemistry.
Aşchie M; Bălţătescu GI; Mitroi A
Rom J Morphol Embryol; 2013; 54(3 Suppl):749-55. PubMed ID: 24322022
[TBL] [Abstract][Full Text] [Related]
13. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
14. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Livasy CA; Karaca G; Nanda R; Tretiakova MS; Olopade OI; Moore DT; Perou CM
Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Munjal K; Ambaye A; Evans MF; Mitchell J; Nandedkar S; Cooper K
Asian Pac J Cancer Prev; 2009; 10(5):773-8. PubMed ID: 20104967
[TBL] [Abstract][Full Text] [Related]
17. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.
Tamimi RM; Colditz GA; Hazra A; Baer HJ; Hankinson SE; Rosner B; Marotti J; Connolly JL; Schnitt SJ; Collins LC
Breast Cancer Res Treat; 2012 Jan; 131(1):159-67. PubMed ID: 21830014
[TBL] [Abstract][Full Text] [Related]
18. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
19. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
20. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
